Hospital Pharmacist’s Preparedness for in-vivo gene therapy medicinal products

The members of the SIG on the hospital pharmacist's preparedness for in-vivo gene therapy medicinal products (financially supported by Pfizer) are looking at the requirements for the handling, preparations and administration of gene therapy products throughout Europe in order to provide guidance and training materials to hospital pharmacists.

 

Survey investigating the preparedness of hospital pharmacies for in-vivo gene therapy medicinal products

Due to the number of licensed formulations on the horizon, the SIG hopes to obtain information on the preparedness of hospital pharmacy departments for the delivery of in-vivo gene therapy medicines to their patients. All information obtained will be kept confidential and will not be used to identify any specific hospitals or individuals.

The survey includes questions touching on the hospital pharmacy facilities and the pharmacists working in these facilities. Hospital pharmacists that are not yet working with in-vivo gene therapies are also encouraged to participate in this survey.

EAHP's SIG is looking to receive one answer per hospital pharmacy/hospital. Participation is completely voluntary. It should take approximately 10 to 20 minutes to complete the survey. Feedback can be shared via the following LINK

Deadline: 19th of June

 

Last update: 24 May 2022